New COVID-19 antibody drug OK’d to protect most vulnerable

U.S. officials have authorized a new COVID-19 antibody drug for people with serious health problems or allergies who can’t get adequate protection from vaccination

Antibody drugs have been a standard treatment for treating COVID-19 infections for over a year. But the AstraZeneca antibody drug cleared by the Food and Drug Administration is different. It’s the first intended for long-term prevention against COVID-19 infection, rather than a short-term treatment.

People who could benefit from the antibody drug include cancer patients, organ transplant recipients and people taking immune-suppressing drugs for conditions like rheumatoid arthritis. Health experts estimate about 2% to 3% of the U.S. population falls into that group.

“These people still have to shelter in place because they’re at really high risk of severe disease and death,” said Dr. David Boulware of the University of Minnesota, ahead of the announcement. “So having this therapy will enable a lot of them to get back to their normal lives.”

Like similar drugs, AstraZeneca’s delivers laboratory-made versions of human antibody proteins, which help the immune system fight off viruses and other infections.

AstraZeneca’s drug would be used differently— only as a long-term preventive measure in people who have increased vulnerability to the virus.

In a company study, people who received Evusheld had a 77% lower risk of infection than people who received a dummy shot over six months, the FDA said.

———

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.

Be the first to comment

Leave a Reply

Your email address will not be published.


*